ALX Oncology

ALX Oncology is a clinical-stage immuno-oncology company dedicated to developing therapies that block the CD47 checkpoint mechanism, which cancer cells exploit to evade the immune system.ALX Oncology’s lead candidate, ALX148, is a next-generation CD47 myeloid checkpoint inhibitor—a fusion protein comprising an engineered high-affinity CD47-binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to maximize the clinical benefits of anti-cancer therapeutic agents and is currently under clinical development for various tumor types.